Aquestive Therapeutics Inc (AQST) Stock Price, Quote & News

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 941 1900

Website: www.aquestive.com

Address:

30 Technology Drive, Warren, United States

Goodstockday Jul. 4 at 2:38 PM

$AQST I am betting that people in the human factors study will be able to follow the new directions and place the film under the tongue after opening the package. I have no concerns about the PK results. When they announce those results weeks from now, the stock price will roughly double. Everything else is just noise at this point. Focus on the big stuff!

2 · Reply

Abetwit Jul. 4 at 1:39 PM

$AQST Bought more.

0 · Reply

BigGainTom Jul. 2 at 8:08 PM

$IOVA $AQST $FLNT nice rallies

0 · Reply

LDstocks2023 Jul. 2 at 6:34 PM

$AQST this stock continues to offer amazing buying opportunities. Buy as much as you can afford to at these levels. Subsequently, you will be gifted with more buying opportunities as the stock continues to slide 5-7% PER DAY! if you start now, you will be able to DCA your way into the 2’s or maybe even the 1’s here in just a few months! when this crl’s again, you can probably even avg down to the .50 - but only if youre lucky and you start investing today! btw…NICE RALLY!!!!!!!

1 · Reply

BigGainTom Jul. 2 at 4:56 PM

$AQST $IOVA $FLNT Nice rallies!!!!

0 · Reply

LDstocks2023 Jul. 2 at 4:31 PM

$AQST nice rally!

0 · Reply

111ggg Jul. 2 at 2:36 PM

$AQST Many bios taking a dive now. It has been a nice ride up for xbi and ibb. They are due for a major pullback.

2 · Reply

SuperGreenToday Jul. 2 at 2:24 AM

$AQST Share Price: $4.24 Contract Selected: Feb 19, 2027 $5 Calls Buy Zone: $0.68 – $0.84 Target Zone: $1.09 – $1.33 Potential Upside: 51% ROI Time to Expiration: 232 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BigGainTom Jul. 1 at 8:01 PM

$IOVA $AQST $FLNT Nice rallies

0 · Reply

BigGainTom Jul. 1 at 5:23 PM

$IOVA $AQST $FLNT Nice rallies

0 · Reply

Aquestive Therapeutics files to sell 230,271 shares of common stock for holders

Jun 26, 2026, 8:00 AM EDT - 8 days ago

Aquestive Therapeutics Registration statement: Registration filing

Jun 10, 2026, 9:30 AM EDT - 24 days ago

Aquestive Therapeutics Transcript: AGM 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Aquestive Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Aquestive Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Aquestive Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Aquestive Therapeutics Slides: Q1 2026

2026-05-13T20:36:49.000Z - 7 weeks ago

Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)

May 13, 2026, 4:01 PM EDT - 7 weeks ago

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 9:31 AM EDT - 7 weeks ago

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

May 6, 2026, 7:00 AM EDT - 2 months ago

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Aquestive Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Aquestive Therapeutics Proxy statement: Proxy filing

2026-04-24T11:41:01.000Z - 2 months ago

Aquestive Therapeutics assumed with an Outperform at Oppenheimer

Apr 16, 2026, 9:00 AM EDT - 2 months ago

AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt

2026-04-15T13:51:38.000Z - 2 months ago

Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims

Apr 9, 2026, 8:23 AM EDT - 3 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

2026-03-30T11:16:34.000Z - 3 months ago

Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA

2026-03-20T11:11:07.000Z - 3 months ago

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

Mar 20, 2026, 7:00 AM EDT - 3 months ago

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A.

Mar 12, 2026, 9:00 AM EDT - 4 months ago

AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt

Mar 10, 2026, 8:25 AM EDT - 4 months ago

Aquestive Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 4:01 PM EDT - 4 months ago

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Mar 9, 2026, 10:40 AM EDT - 4 months ago

Aquestive Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 2:01 PM EST - 4 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2026-03-05T18:20:15.000Z - 4 months ago

Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global

Mar 5, 2026, 8:00 AM EST - 4 months ago

Aquestive Therapeutics Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

Aquestive Therapeutics Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

Aquestive Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

Aquestive Therapeutics Slides: Q4 2025

2026-03-04T21:20:27.000Z - 4 months ago

Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

2026-03-04T21:19:36.000Z - 4 months ago

Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M

Mar 4, 2026, 4:01 PM EST - 4 months ago

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 12:00 PM EST - 4 months ago

Aquestive Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 4 months ago

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 7:00 AM EST - 4 months ago

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

2026-02-20T12:06:15.000Z - 4 months ago

Aquestive announces poster presentations on Anaphylm at AAAAI meeting

2026-02-18T12:11:06.000Z - 4 months ago

Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer

2026-02-03T13:46:32.000Z - 5 months ago

Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street

2026-02-02T19:05:09.000Z - 5 months ago

Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating

2026-02-02T15:45:14.000Z - 5 months ago

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

2026-02-02T15:40:09.000Z - 5 months ago

Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

Feb 2, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Transcript: Status update

Feb 2, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Press release: Status update

Feb 2, 2026, 8:00 AM EST - 5 months ago

Aquestive Therapeutics Slides: Status update

2026-02-02T12:12:20.000Z - 5 months ago

Aquestive Therapeutics announces FDA issuance of CRL for Anaphylm

Feb 2, 2026, 7:10 AM EST - 5 months ago

US FDA declines to approve Aquestive's oral drug for allergic reactions

Feb 2, 2026, 7:00 AM EST - 5 months ago

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Jan 9, 2026, 7:00 AM EST - 6 months ago

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Dec 4, 2025, 10:00 AM EST - 7 months ago

Aquestive Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 8:00 AM EST - 8 months ago

Aquestive Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Aquestive Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Aquestive Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 8 months ago

Aquestive Therapeutics Slides: Q3 2025

Oct 27, 2025, 7:00 AM EDT - 8 months ago

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Oct 8, 2025, 7:00 AM EDT - 9 months ago

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Sep 28, 2025, 6:00 PM EDT - 9 months ago

Aquestive Therapeutics Slides: Corporate Presentation

Sep 8, 2025, 10:00 AM EDT - 10 months ago

Aquestive Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Aquestive Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 14, 2025, 6:28 AM EDT - 11 months ago

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aug 14, 2025, 6:00 AM EDT - 11 months ago

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Aquestive Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Aquestive Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Aquestive Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Aquestive Therapeutics Slides: Q2 2025

Aug 11, 2025, 4:01 PM EDT - 11 months ago

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Goodstockday Jul. 4 at 2:38 PM

2 · Reply

Abetwit Jul. 4 at 1:39 PM

$AQST Bought more.

0 · Reply

BigGainTom Jul. 2 at 8:08 PM

$IOVA $AQST $FLNT nice rallies

0 · Reply

LDstocks2023 Jul. 2 at 6:34 PM

1 · Reply

BigGainTom Jul. 2 at 4:56 PM

$AQST $IOVA $FLNT Nice rallies!!!!

0 · Reply

LDstocks2023 Jul. 2 at 4:31 PM

$AQST nice rally!

0 · Reply

111ggg Jul. 2 at 2:36 PM

$AQST Many bios taking a dive now. It has been a nice ride up for xbi and ibb. They are due for a major pullback.

2 · Reply

SuperGreenToday Jul. 2 at 2:24 AM

0 · Reply

BigGainTom Jul. 1 at 8:01 PM

$IOVA $AQST $FLNT Nice rallies

0 · Reply

BigGainTom Jul. 1 at 5:23 PM

$IOVA $AQST $FLNT Nice rallies

0 · Reply

InnerVoice Jul. 1 at 4:28 PM

$AQST In my Fidelity account, the StarMine equity score for AQST was just raised from 2.3 (bearish) to 5.3 (neutral). So that is a positive change.

1 · Reply

111ggg Jul. 1 at 1:40 PM

$AQST should be another decent day for bios with funds moving out of tech. Just dont know which bios get the action from day traders.

0 · Reply

kibli Jul. 1 at 1:18 PM

$AQST Next ER projected any day Aug 6-12 will provide several catalysts. A beatdown of EPS is expected, along with 108 news, updates (results) of PK trial and expected resubmission for 109. Not long to wait for outstanding news.

0 · Reply

Outrageous Jul. 1 at 12:55 PM

$AQST Buckle up, Q3 has officially started, next 30 days will be quite interesting in my opinion. Wishing everyone a very happy, safe and God Blessed 4th of July. Happy 250th America

1 · Reply

shawn45 Jun. 30 at 11:36 PM

$OTLK I am about to buy 10,000 shares right now - ZACKS UPGRADED OTLK from HOLD to BUY -2 NOW. Looks like huge upside is coming up.. $NVDA $AQST $MU $AMZN

3 · Reply

shawn45 Jun. 30 at 11:14 PM

$AQST This company still haven't finished the PK Studies. By the end of Q3 we will know the outcome on the PK Studies. They will have US FDA TYPE A Meeting and then if all ok, they will resubmit. Still long way to go.. Patiently waiting

2 · Reply

BigGainTom Jun. 30 at 7:23 PM

$AQST $IOVA $FLNT Nice rallies

2 · Reply